Allergic rhinitis and allergic conjunctivitis
Diagnosing allergic rhinitis and conjunctivitis, the ARIA-EAACI 2024-2025 intranasal treatment ladder, allergen immunotherapy, thunderstorm asthma, and the eye presentations that need an ophthalmologist.
Tier 1Condition
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- Allergic rhinitis affects about 1 in 5 Australians, one of the highest rates in the world. It is IgE-mediated inflammation of the nasal mucosa after exposure to an aeroallergen.
- It travels with asthma (most people with asthma have rhinitis, and rhinitis predicts asthma), atopic dermatitis and allergic conjunctivitis.
- Treatment rests on intranasal corticosteroid, with an intranasal antihistamine-corticosteroid combination when that isn't enough. The ARIA-EAACI 2024-2025 revision (published December 2025) now suggests the combination over either drug alone.
Loading the rest of the note…
Finished reading?
Sources
- Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines 2024-2025 Revision. Part I: Guidelines on Intranasal Treatments (Sousa-Pinto B et al. Allergy 2026;81(4):954-976)ARIA and EAACI, 2024-2025 revision (published December 2025)
- ASCIA Aeroallergen Immunotherapy GuideAU/NZASCIA (Australasian Society of Clinical Immunology and Allergy), 2024
- ASCIA Allergen Immunotherapy FAQAU/NZASCIA, 2024
- Therapeutic Guidelines: Respiratory and Ophthalmology (allergic rhinitis, allergic conjunctivitis)AU/NZTherapeutic Guidelines Limited
- Australian Asthma Handbook (allergic rhinitis and specific allergen immunotherapy)AU/NZNational Asthma Council Australia
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Personal emails, About story and Australian-style copy